SCHEMBL2890255

SCHEMBL2890255

O=C1c2ccccc2C(=O)N1c1ccccc1Oc1ccccc1N1C(=O)c2ccccc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
NR1H3 Q13133 4/20 0.54
POLB P06746 1/20 0.53
NR1H2 P55055 4/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ALDH1A1 P00352 3/20 0.50
CASP6 P55212 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HTT P42858 1/20 0.50
GAA P10253 2/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950727 0.89 NR1H2 (0.67) KMT2AMEN1NR1H3POLBNR1H2
SCHEMBL29168849 0.84 KMT2A (0.76) KMT2AMEN1NR1H3NR1H2ALDH1A1
SCHEMBL30758650 0.84 KMT2A (0.76) KMT2AMEN1NR1H3NR1H2ALDH1A1
SCHEMBL4649466 0.82 POLB (0.65) KMT2AMEN1NR1H3POLBNR1H2
SCHEMBL11872977 0.80 NPC1 (0.59) KMT2AMEN1NR1H3POLBNR1H2
SCHEMBL2892688 0.79 NR1H2 (0.49) KMT2AMEN1NR1H3POLBNR1H2
SCHEMBL28450172 0.78 MEN1 (0.51) KMT2AMEN1NR1H3POLBNR1H2
SCHEMBL9806801 0.77 LMNA (0.70) KMT2AMEN1POLBNR1H2SMN1; SMN2
SCHEMBL9320871 0.77 MGLL (0.71) NR1H2ALDH1A1MGLL
SCHEMBL10398325 0.75 MGLL (0.69) NR1H2ALDH1A1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660560-B1 PHASE TRANSFER CATALYZED METHOD FOR PREPARATION OF POLYETEHRIMIDES SABIC GLOBAL TECHNOLOGIES BV (NL) 2016-03-23 EP disclosed
US-7714095-B2 Phase transfer catalyzed method for preparation of polyetherimides SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-05-11 US disclosed
US-7605222-B2 Gel permeation chromatography; isomeric bis(phthalimide) and bisphenol-a structural units SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2009-10-20 US disclosed
EP-1660556-B1 COPOLYETHERIMIDES SABIC INNOVATIVE PLASTICS IP (NL) 2009-05-13 EP disclosed
EP-1989246-A2 PHASE TRANSFER CATALYZED METHOD FOR PREPARATION OF POLYETHERIMIDES Sabic Innovative Plastics IP B.V. (NL) 2008-11-12 EP disclosed
WO-2007100473-A2 PHASE TRANSFER CATALYZED METHOD FOR PREPARATION OF POLYETHERIMIDES SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2007-09-07 WO disclosed
US-20070043203-A1 Gel permeation chromatography; isomeric bis(phthalimide) and bisphenol-a structural units GENERAL ELECTRIC COMPANY (US) 2007-02-22 US disclosed
US-20060173158-A1 Phase transfer catalyzed method for preparation of polyetherimides GENERAL ELECTRIC COMPANY (US) 2006-08-03 US disclosed
EP-1660556-A1 COPOLYETHERIMIDES GENERAL ELECTRIC COMPANY (US) 2006-05-31 EP disclosed
EP-1660560-A2 PHASE TRANSFER CATALYZED METHOD FOR PREPARATION OF POLYETEHRIMIDES GENERAL ELECTRIC COMPANY (US) 2006-05-31 EP disclosed
WO-2005023901-A1 COPOLYETHERIMIDES GENERAL ELECTRIC COMPANY (US) 2005-03-17 WO disclosed
WO-2005021618-A2 PHASE TRANSFER CATALYZED METHOD FOR PREPARATION OF POLYETEHRIMIDES GENERAL ELECTRIC COMPANY (US) 2005-03-10 WO disclosed
US-20050049390-A1 Phase transfer catalyzed method for preparation of polyetherimides GENERAL ELECTRIC COMPANY 2005-03-03 US disclosed
US-6849706-B1 Copolyetherimides GENERAL ELECTRIC COMPANY (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173158-A1 Phase transfer catalyzed method for preparation of polyetherimides TRRAP, RCC1, DDT KMT2A 326/4885MEN1 4568/4885NR1H3 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.